Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma

in Leukemia & Lymphoma (2012), 53(12), 2515-16

Obesite, insulinoresistance et diabete de type 2: facteurs de risque du cancer du sein.

in Revue Médicale de Liège (2011), 66(5-6), 238-44

Obesity and type 2 diabetes are two risk factors of breast cancer, especially after menopause. Underlying mechanisms are multiple and include hyperinsulinism due to insulin resistance (insulin, as insulin ... [more ▼]

Obesity and type 2 diabetes are two risk factors of breast cancer, especially after menopause. Underlying mechanisms are multiple and include hyperinsulinism due to insulin resistance (insulin, as insulin-like-growth factor -IGF-, is a growth factor), hyperleptinaemia associated with hypoadiponectinaemia, and high levels of estrogens resulting from aromatization of androgens in adipose tissue. In presence of type 2 diabetes associated with obesity, hyperglycaemia might provide energy substrate promoting tumour growth. These data have therapeutic implications with expected favourable effects of weight loss, resulting in a reduction of fat mass and insulin resistance, and the promising results recently reported with metformin contrasting with the negative effects of exogenous administration of high doses of insulin. [less ▲]

Activite anticancereuse de la metformine: nouvelles perspectives pour une vieille molecule.

in Revue Médicale Suisse (2010), 6(260), 1601-7

Le diabète de type 2 est associé à un risque accru de cancer, d’autant plus évident qu’on maîtrise mieux la mortalité cardio-vasculaire. Tous les traitements antidiabétiques n’ont pas le même impact sur ... [more ▼]

Le diabète de type 2 est associé à un risque accru de cancer, d’autant plus évident qu’on maîtrise mieux la mortalité cardio-vasculaire. Tous les traitements antidiabétiques n’ont pas le même impact sur le cancer : le risque est accru avec les sulfonylurées et diminué avec la metformine (et les glitazones). De nombreuses études épidémiologiques observationnelles et cas-témoins récentes révèlent qu’un traitement par metformine est associé à une nette réduction de l’incidence de néoplasies et de la mortalité par cancer. Il existe une relation doseréponse et une relation entre la durée préalable du traitement par metformine et l’effet protecteur observé. Les mécanismes invoqués sont l’activation de l’enzyme AMPK et l’inhibition de la voie mTOR. Des études avec la metformine sont en cours en oncologie, notamment dans le cancer du sein. [less ▲]

"Metaboliquement obeses" sans exces de poids: un phenotype interpellant.

in Revue Médicale de Liège (2009), 64(1), 14-22

Obesity, especially abdominal obesity, is the main risk factor of metabolic syndrome. However, there are obviously non obese individuals who are metabolically abnormal and therefore exposed to an ... [more ▼]

Obesity, especially abdominal obesity, is the main risk factor of metabolic syndrome. However, there are obviously non obese individuals who are metabolically abnormal and therefore exposed to an increased risk of cardiovascular complications. Unfortunately, those persons fail to be detected because of a falsely reassuring body weight. The present paper aims at better understanding the etiopathogenesis and pathophysiology of this particular phenotype, at evaluating its potential clinical consequences and at describing the main principles of its therapeutic management. [less ▲]

Sujets « métaboliquement obèses » de poids normal. Seconde partie: pronostic et prise en charge

in Obésité (2008), 3(4), 280-285

Metabolically obese normal-weight (MONW) individuals are frequently not detected because of a falsely reassuring body weight. However, they have most of the metabolic syndrome markers known to be ... [more ▼]

Metabolically obese normal-weight (MONW) individuals are frequently not detected because of a falsely reassuring body weight. However, they have most of the metabolic syndrome markers known to be associated with a higher risk of type 2 diabetes, cardiovascular disease and mortality. The present review paper aims to describe the clinical consequences to which MONW people are exposed and the main principles of managing this syndrome [less ▲]